Shengen Bio Completes Over $110 Million Series B Financing to Advance Clinical-Stage RNAi Therapeutics

On December 8, 2025, SANEGENEBIO announced the successful completion of a Series B financing round exceeding US$110 million. This round was led by a well-known industry institution, with participation from an international sovereign fund, China Biopharmaceutical Group, Legend Capital, Vivo Capital, Invus, SymBiosis, Suzhou Venture Capital, Zhenmai Investment, and Lake Bleu Capital. Additionally, it received strategic investment from Eli Lilly and Company. Existing shareholders including GL Ventures, Qiming Venture Partners, K2VC Fund, TF Capital, Oriza Holdings, and Northern Light Venture Capital continued their support. The proceeds from this financing will primarily be used to accelerate the advancement of clinical-stage pipelines into registrational clinical studies and expedite the development progress of multiple therapeutic projects.

SANEGENEBIO, founded in 2021, is a globally integrated clinical-stage biotechnology company dedicated to developing innovative RNAi therapies with "First-in-Class" and "Best-in-Class" potential to address significant unmet clinical needs in obesity, cardiometabolic diseases, autoimmune disorders, and immune-mediated conditions. The company was established by a pioneering team with deep R&D experience in the RNAi field and has research centers in Suzhou and Shanghai, China, as well as Boston, USA, receiving ongoing support from several renowned domestic and international investment institutions.

Leveraging its proprietary GalNAc liver-targeted delivery platform and the industry-leading LEAD™ (Ligand and Enhancer Assisted Delivery) extrahepatic delivery platform, SANEGENEBIO can efficiently, safely, and durably deliver siRNA precisely to the liver as well as extrahepatic tissues such as fat, muscle, immune cells, and the central nervous system. This significantly reduces dosing frequency, enhancing treatment adherence and efficacy. Currently, the company has established a diversified product pipeline covering multiple major disease areas, including four clinical-stage drug candidates (one in Phase II and three in Phase I) and several preclinical projects. Following the successful completion of its Series B financing, SANEGENEBIO will further accelerate the global clinical development and registration process for its R&D pipeline, promoting RNAi therapies as standard treatments across more disease areas and bringing transformative next-generation therapeutic options to patients worldwide.

E.N.D

ForPromote Cooperation and Technical Exchange in the Cell and Gene Therapy IndustryThe team of the WeChat Official Account "Cell and Gene Therapy Field" has established a professional communication group for cell and gene therapy. Press and hold the QR code below to add the editor's WeChat and join the group. Due to the large number of applicants, please include the following information when adding WeChat: Institution/Enterprise—Major/Position—Name. If you are a PI/Professor/Manager or above, please also indicate.